Finance Bill Aims To Reform PBM Policies On Biosimilar Access

November 6, 2023 at 4:56 PM
Failure of the first biosimilar alternative to the high-cost drug Humira (adalimumab) to capture meaningful market share shows that formulary decisions by pharmacy benefit managers (PBMs) can substantially reduce the savings potential for patients of biosimilar drugs, according to health care consultants, but that could be changed by provisions of a Senate Finance Committee bill set to be marked up this week. Experts say Humira’s manufacturer AbbVie was able to keep biosimilars from capturing any significant market share by offering...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.